AMYRA Successfully Demonstrates a New Therapeutic Paradigm for Gluten-Related Disorders in a First-in-Human Study
23 oct. 2024 04h00 HE | AKAMPION
Lead product AMYNOPEP achieves proof-of-principle in exploratory clinical studyAMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical...
barinthuslogo.jpg
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
24 sept. 2024 08h00 HE | Barinthus Biotherapeutics
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
Entero-Logo-Options-FINAL.png
Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
10 sept. 2024 07h00 HE | Entero Therapeutics, Inc.
BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Canadian Post Second
Canadian Post Secondary Institutions Fall Short on Gluten-Free Accommodations
27 août 2024 15h56 HE | Celiac Canada
Toronto, ON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- A recent survey conducted by Celiac Canada reveals that Canadian universities and colleges are not providing adequate gluten-free accommodations on...
Barinthus Biotherapeutics Pipeline
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
08 août 2024 08h00 HE | Barinthus Biotherapeutics
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
Entero-Logo-Options-FINAL.png
Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
31 juil. 2024 07h00 HE | Entero Therapeutics, Inc.
BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
VMR Logo.png
Gluten Free Products Market Surges to USD 8.73 Billion by 2031, Propelled by 7.20% CAGR - Verified Market Research®
18 juil. 2024 10h00 HE | Verified Market Research
Lewes, Delaware, July 18, 2024 (GLOBE NEWSWIRE) -- The Global Gluten Free Products Market Size is projected to grow at a CAGR of 7.20% from 2024 to 2031, according to a new report published by...
barinthuslogo.jpg
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
12 juin 2024 16h01 HE | Barinthus Biotherapeutics
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Entero-Logo-Options-FINAL.png
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
22 mai 2024 07h00 HE | Entero Therapeutics, Inc.
BOCA RATON, Fla., May 22, 2024 (GLOBE NEWSWIRE) --  Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (Nasdaq: ENTO) (“Entero” or the “Company”), a late clinical-stage...
Entero-Logo-Options-FINAL.png
Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference
20 mai 2024 07h00 HE | Entero Therapeutics, Inc.
BOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...